Toku Eyes

|	
Sector	Tech
Sub-sector	Health Tech
Capital raise	NZ$10 – 15million
Min Investment	NZ$750,000
Looking for	The ideal investor will have experience in eyecare, ophthalmic device manufacturing or private insurance with connections into eyecare markets overseas. We would also consider high net worth investors or strategic partners who would assist us with commercialisation and export of this product.
Web-links	• www.tokueyes.com • https://www.linkedin.com/company/26488605/

Diabetes related eye health checks are mandated as part of Optometrists and Ophthalmologists' clinical duties. THEIA™ is an Artificial Intelligence (AI) that can perform these checks using retinal photographs , and in 75% of cases eliminates the need of clinician's involvement. THEIA(TM) was tested on more than 60000 patients in New Zealand had achieved 99.8% negative predictive value(NPV), in identifying referable disease. The inference takes less than a minute per patient, increasing the capacity for eyecare practitioners by 50%, while reducing the cost of screening by 30%.

Summary

THEIA™ is an artificial intelligence (AI) enabled clinical tool that diagnoses diabetic retinopathy with 99.8% NPV. By instantly delivering a diagnostic report to the eyecare professional, this solution will double the vision health check capacity for eyecare professionals while reducing the cost to them by one third. More patients can be examined & accurately diagnosed on the spot as either requiring clinical treatment or not. As pre-diabetic and diabetic patients' eye exams can be processed more quickly, early detection of diabetic retinopathy will lead to shorter wait times for clinical treatment. An additional benefit is that optometrists and opthalmologists can then spend more time applying medical interventions such as glasses, contact lenses, injections and surgical operations, increasing the revenue of the eye care practice.

Challenge
Diabetes is a growing Regional & Global Problem

2017
245,700
of NZ's 4.8 m
diagnosed with
diabetes
=
5.1%

642m
ADULTS LIVING WITH DIABETES

415m
ADULTS LIVING WITH DIABETES

YEAR 2040

YEAR 2015

(35%) 224m
HAVE SOME FORM OF DR

145m (35%)
HAVE SOME FORM OF DR

(11%) 70m
HAVE VISION-THREATENING DR

45m (11%)
HAVE VISION-THREATENING DR

Early Detection Vital To Avoid Long Term Loss of Sight

Background

Diabetes is a prolific disease projected to grow to an alarming 642 million patients worldwide by 2040. Diabetic retinopathy is a secondary condition from diabetes which if left untreated can rob patients of their eyesight.

Toku Eyes was founded by bioengineer Ehsan Vaghefi, ophthalmologist David Squirrell and chemist Diana Siew. Together, they designed, created and verified THEIA as an AI that automates the diagnostic analysis of vision health check results and eliminates the need for clinical interaction for 75% of patients. In doing so, THEIA shortens the time taken to diagnose patient eye health and increases the diagnostic accuracy delivering cost savings and increased patient throughput.

DHB Screening Process

Process	Component	Step 1	Step 2	Step 3	Step 4			
Theia-DR	Clinical Process	Fundus Photo	Instant Report Red 20% Green 80% Explains to Px	Referral	Specialist Px Explanation & Treatment	Expense & Time Saving Productivity Increase Improved Health Outcomes		
	Px Journey	Appointment	Instantly informed and advised of next steps/Referral	Instant appointment Active wait	Appointment	Focus on wellbeing with certainty		

Process	Component	Step 1	Step 2	Step 3	Step 4	Step 5	Step 6	Step 7
Current	Clinical Process	Fundus Photo	Clinician Opens for review	Reviews 100%	Grading & Classification	Report	Referral in the ABSENCE of patient	Specialist Px Explanation & Treatment
	Px Journey	Appointment	Departs	6 – 8 weeks of Waits/Uncertainty			Told of Appointment	Appointment

Application of Funds & Timeline

Primary
- User Interface
- Commence Approval Applications
- Launch in NZ - DHB

Component	Major Milestones	2020	2021	2022	2023
Product Development	User interface development				
Product Development	Registration FDA Start				
Product Development	Registration TGA				
Infrastructure	Stack Servers				
Capital	Capital Raise				
Markets	NZ DHB Implementation				
Markets	NZ Independent Optometrists				
Markets	Australia				
Markets	International				
Markets	Expand base & Revenue				
Exit	Exit				

Use of Funds

Funds raised will be used to obtain TGA approval for Australian market entry, creating a customer support team, and developing market strategy for UK, US, Malaysia and Singapore (due to similarities in diabetic screening services).

Looking for

Capital raise   NZ$10 – 15million
Min Investment   NZ$750,000

The ideal investor will have experience in eyecare, ophthalmic device manufacturing or private insurance with connections into eyecare markets overseas. We would also consider high net worth investors or strategic partners who would assist us with commercialisation and export of this product.

For more information please contact

Suzanne McKinnon
Investment Specialist
Auckland Unlimited
M + 64 21 243 1373
E Suzanne.McKinnon@aucklandnz.com